Abstract 141P
Background
The cultivation mode for tumor stem cells generally involves sorting. Fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS) are the main techniques for sorting CSCs. However, this is not the optimal solution. FACS is time-consuming, technically demanding, and yields a limited number of sorted cells. MACS, while operationally simple, can only sort one marker at a time. Conditional culture media require the addition of a large quantity of expensive growth factors. We established a dynamic suspension culture without additional sorting and cytokines to obtain cancer stem cell.
Methods
A dynamic suspension culture system without sorting and additional cytokines was used to obtain cancer stem cells. The immunostaining, RNA-seq, metabolomics and proteomics were performed to analyze the properties of cancer stem cells.
Results
The cancer stem cell was successfully cultivated from unconditionally dynamic suspension culture system. They exhibited the expression of specific cancer stem markers, such as upregulated CD44, CD133, ALDHA1, ABCB5 and decreased CD24.These cells possessed self-renewal capability and strong tumorigenicity. Meanwhile, their transcriptome, metabolism, proteins were reprogrammed. Drug metabolism cytochrome P450 and resistance to many drugs, such as platinum and methotrexate were activated. A metabolic switch from glycolysis to oxidative phosphorylation was founded in these cells. Importantly, actin cytoskeleton rearrangement and epithelial-mesenchymal transition were observed in these cells. The RNA-seq analyses show that signaling pathways, including HIF, Hippo and Wnt pathway were activated, resulting in the remodeling of cancer stem cell.
Conclusions
Independently sorting and the addition of cytokines, a dynamic suspension culture system can successfully generate cancer stem cells. These cells exhibited typical cancer stem cell properties, including reprogrammed transcriptome, metabolism, and protein levels. This unconditional dynamic suspension culture system offers an alternative method for cultivating cancer stem cells and presents a novel model for exploring their characteristics.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes
Presenter: Rowan Howell
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
Presenter: Giorgia Bortolus
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Physician perceptions and the evolving landscape of next generation sequencing (NGS) use across EU4+UK
Presenter: Keerun Khela
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)
Presenter: Phoebe Cheng
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Clinical implementation of NGS and ESCAT for optimized cancer therapy
Presenter: AI. Martin-Quesada
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Prevalence of homologous recombination repair deficiency-associated variants in non-selected Portuguese patients with metastatic prostate cancer
Presenter: Tiago Barroso
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany
Presenter: Maike Collienne
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Molecular tumor board for advanced cancer patients offers new therapeutic opportunities beyond level 1 ESCAT scale
Presenter: Victor Segui-Manzaneque
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - NICE recommendations and ESMO-MCBS/ESCAT scores for solid tumour drugs
Presenter: Eunice Xing
Session: Cocktail & Poster Display session
Resources:
Abstract